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Abstract (246 words) 
 
Background The platelet collagen receptor glycoprotein VI (GPVI) contributes significantly 
to platelet adhesion and thrombus formation. This study examined the platelet surface 
expression of GPVI in patients with transient ischemic attack (TIA) and stroke. 
Methods and results We consecutively evaluated 205 patients, who admitted the stroke unit 
with symptoms for stroke.  Surface expression of the platelet activation markers (GPVI, 
CD62P, GPIb) was determined by two-color whole blood flow cytometry. Patients with TIA 
as well as with stroke showed a significantly enhanced GPVI expression on admission 
compared to patients with non-ischemic (NI) events (TIA (mean fluorescence intensity (MFI) 
+ SD): 20.9±7.1 vs. NI: 16.2±3.9; p=0.002; stroke: 20.4±5.7 vs. NI; p=0.002), whereas 
CD62P surface expression showed a significant elevation in TIA and merely a trend in stroke 
(TIA vs. NI: 12.8±4 vs. 10.9±3.6; p=0.048; stroke: 12.6±7.9 vs. NI; p=0.145). Logistic 
regression analysis revealed that on admission GPVI was associated with stroke independent 
of conventional laboratory markers such as C-reactive protein, blood glucose, and creatine 
kinase. Using a receiver operating characteristic (ROC) curve on GPVI, we have determined 
the cut off value of 18.2 for stroke. The area under the curve was 0.683 (95%CI, 0.585 to 
0.757). Thus, patients with enhanced GPVI expression levels (≥18.2) had a 2.4 fold relative 
risk for stroke. Patients with elevated platelet GPVI expression level had a poorer clinical 
outcome in cumulative event-free survival for stroke, myocardial infarction, and cerebro-
/cardiovascular death at three-month follow-up (Log rank; p=0.045).  
Conclusion Platelet GPVI surface expression is significantly enhanced in patients with TIA 
and stroke compared to patients with NI events. Determination of platelet-specific GPVI may 
be useful as an early biomarker for cerebral ischemia.  
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Introduction 
Apart from acute coronary syndrome (ACS), acute ischemic stroke takes an enormous toll of 
life in the Western countries.1 Management of acute ischemic stroke is strongly based on 
clinical assessment. Early diagnosis of stroke is important for the determination of the type 
(ischemic or hemorrhagic) and the subtype classification (e.g. TOAST) in order to start proper 
treatment rapidly.2 Although the distinction between transient ischemic attack (TIA) and 
ischemic stroke has blurred over the last years, they share similar pathogenetic mechanisms.3 
Several new potential biomarkers have emerged to facilitate diagnosis of ischemic 
stroke. Beside markers for glial activation and neuronal and endothelial cell injury like S-
100B, myelin basic protein, neuron-specific enolase (NSE), and soluble thrombomodulin, 
particularly markers for inflammation like C-reactive protein (CRP), matrix-
metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-
1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) as well as von Willebrand 
factor (vWF) and P-selectin have been examined.4-10  However, despite of promising results 
with enhanced serum and/or plasma concentrations correlating to stroke and to clinical 
outcome, none of these biomarkers is established and considered to be useful in clinical 
routine yet. Likewise in patients with acute coronary syndrome (ACS), increases in 
biomarkers upstream from biomarkers of tissue damage or necrosis such as markers of 
inflammation and thrombosis may provide an earlier assessment of overall patient risk and 
help in identifying patients at risk of a cerebrovascular event. Platelets play a key role in 
arterial thrombosis, ACS and stroke. Exposure of collagen to the bloodstream in acute plaque 
rupture triggers sudden platelet activation and formation of a platelet plug. The following 
activation of the coagulant cascade leads to the development of a firm fibrin-containing 
thrombus and vessel occlusion.11 
Recently, we demonstrated that the surface expression of platelet collagen receptor  
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glycoprotein VI (GPVI) is elevated in patients with ACS and associated with acute coronary 
events.12,13 
The aim of the present study was to evaluate platelet GPVI levels in patients presenting with 
symptoms of acute cerebrovascular disease and to define GPVI as biomarker for acute stroke.   
 
 
Methods 
Study population and enrolment criteria 
Our study population comprised 205 consecutive patients, who presented with symptoms of 
stroke. Among these patients, 133 (64.9%) presented with stroke, 18 (8.8%) with TIA, and 54 
(26.3%) with non-ischemic (NI) events, which served as controls. All of these patients have 
received cranial imaging (CT scan). 38 patients with stroke received a lysis therapy according 
to the CLOTBUST trial protocol.14 
           The exclusion criteria were age below 18 years, inability and lack of informed consent.  
Clinical outcome was performed by a predefined structured telephone interview after a 3-
month follow-up (92.2%: 189 of 205 patients). 
 
Definitions 
TIA: Transient ischemic attack was defined by the duration of symptoms of stroke less than 24 
hours.3 
Stroke: Stroke was considered with symptoms lasting more than 24 hours after the onset or 
with the evidence of an acute clinically relevant brain lesion in patients with rapidly vanishing 
symptoms using cranial imaging (CT scan).3  
TOAST: The origin of cerebral ischemia was classified according to the Trial of Org10172 in 
Acute Stroke Treatment (TOAST) criteria according to Adams et al.: 1) large-artery 
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atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion, 4) stroke of other determined 
etiology, 5) stroke of undetermined etiology.2  
Non-ischemic Events: patients provided one of the following disorders: epileptic attacks,  
medication interaction, transient visual disorder, paroxysmal positioning vertigo, migraine 
with aura, psychogen, brain tumor, cerebral bleeding, alcohol abuse. 
NIHSS: Stroke severity was assessed with the National Institutes of Health Stroke Scale 
(NIHSS).15  
 
Sample collection  
Blood was drawn from the anticubital vein on time of admission to hospital. The blood was 
filled into 5 mL citrate phosphate dextrose adenine vials, processed and analyzed immediately 
by flow cytometry as described.12,13,16  
 
FACS analysis 
The surface expression of the platelet receptors GPVI, CD62P, and GPIb was determined by 
two-color whole blood flow cytometry, as previously described.16,17 Mean fluorescence 
intensity (MFI) was used as the index of receptor expression. Fluorescein (FITC)-conjugated 
anti-CD62P (clone CLB-Thromb/6) and phycoerythrin (PE)-conjugated anti-CD42b (clone 
SZ2) monoclonal antibodies (mAb) were purchased from Immunotec, Beckman Coulter, Inc., 
USA. The fluorescein (FITC)-conjugated anti-GPVI mAb 4C9 was generated and 
characterized, as previously described.18,19 
 
Statistics 
A probability value of less than 0.05 was considered as statistical significant. Adjustment by 
possible confounders was performed by the multifactorial analysis of covariance for the 
decadic logarithm of GPVI. Association of the platelet GPVI surface expression was found to 
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be independent of medical treatment at the time of admission, cerebrovascular risk factors, 
age and gender. The association of GPVI after adjustment for conventional laboratory 
markers was assessed by the logistic regression analysis in patients under suspicion for stroke. 
Mean values between two categories were compared with a two-tailed unpaired t-test. In 
order to predict the individual risk for stroke by using the levels of GPVI, we calculated the 
receiver operating characteristic (ROC) curve.  
A log-rank test (Mantel-Cox) was applied for the evaluation of associations between event 
and variables. All statistical analyses were performed using SPSS version 15.  
 
 
Results 
We consecutively investigated the platelet surface expression of collagen receptor GPVI in a 
total of 205 patients for suspected stroke. In all patients the diagnosis was determined by the 
duration of symptoms and by cranial imaging (CT scan). The demographic details are given in 
Table 1.    
Patients with TIA (n=18) as well as with stroke (n=133) showed a significantly 
enhanced GPVI expression on admission compared to patients with non-ischemic (NI) events 
(n=54) (TIA (mean fluorescence intensity (MFI)±SD): 20.9±7.1 vs. NI: 16.2±3.9; p=0.02; 
stroke: 20.4±5.7 vs. NI; p=0.002), whereas CD62P surface expression showed a significant 
elevation in TIA and merely a trend in stroke (TIA vs. NI: 12.8±4 vs. 10.9±3.6; p=0.048; 
stroke: 12.6±7.9 vs. NI; p=0.145) (Figure 1A). GPIb expression tended to decrease with 
increased platelet activation (TIA vs. NI: 142.7±49.6 vs. 149.7±45; p=0.543; stroke: 
138.1±42.7 vs. NI; p=0.447). There are no differences in the degree platelet activation 
between patients with TIA and those with ischemic stroke (GPVI: p=0.881; CD62P: p=0.293) 
(Figure 1A). Ischemic stroke was further itemized according to TOAST classification.2 
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Patients with large-artery atherosclerosis (TOAST1) and cardioembolism (TOAST2) have 
shown significantly increased GPVI levels in contrast to patients with non-ischemic events 
(TOAST1: 20.1±6.1 vs. NI; p=0.002; TOAST2: 22.2±6.3 vs. NI; p=0.002), whereas CD62P 
surface expression showed no significant difference (TOAST1: 12±4.3 vs. NI; p=0.253; 
TOAST2: 14±12.1 vs. NI; p=0.328) (Figure 1B), nor GPIb expression presented with no 
significant difference (TOAST1: 138.3±41.8 vs. NI; p=0.448; TOAST2: 144.9±58.1 vs. NI; 
p=0.796). We found no correlation between platelet surface GPVI expression and the severity 
of stroke assessed by NIHSS (r=-0.19; p=0.789) (Figure 1C).15 
 To evaluate whether GPVI is associated with stroke independent of baseline 
conventional laboratory markers, we performed a logistic regression analysis that included C-
reactive protein, blood glucose, and creatine kinase, determined at time on admission (Table 
2). We found that GPVI platelet surface expression was independently associated with stroke 
(Table 2).           
Comparison of the decadic logarithm of GPVI was adjusted by possible confounders 
such as age, gender, medical treatment and cerebrovascular risk factors. 
To predict the individual risk for stroke by using the levels of GPVI, we calculated the 
receiver operating characteristic (ROC) curve (Figure 2A). The cut off value for stroke was 
18.2. The area under the curve was 0.683 (95%CI, 0.585 to 0.757). Patients with GPVI levels 
of ≥18.2 had a 2.4-fold relative risk (95%CI, 1.4 to 4.2) for stroke (Figure 2B).  Patients with 
an elevated platelet GPVI expression level (MFI≥18.2) had a poorer clinical outcome than 
patients with a lower GPVI expression level (MFI<18.2) (Table 3). Particularly, three-month 
follow-up reached a statistical significant level in cumulative event-free survival for stroke, 
myocardial infarction, and cerebro-/cardiovascular death (Log rank; p=0.045) (Figure 3). The 
clinical outcome in our patients was not influenced by the medication since patients had been 
administered comparable therapeutic regimes consisting of statins and antiaggregatory 
therapy (Table 4).  
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Discussion 
The major findings of the present study are that (1) enhanced platelet collagen receptor 
GPVI expression is associated with TIA and stroke, (2) GPVI was associated with stroke 
independent of conventional laboratory markers such as C-reactive protein, blood glucose, 
and creatine kinase, and (3) patients with an elevated platelet GPVI expression level 
(MFI≥18.2) had a poorer clinical outcome in cumulative event-free survival for stroke, 
myocardial infarction, and cerebro-/cardiovascular death at three-months follow-up. 
Previous studies suggested that platelets play an important role in the development of 
transient brain ischemia or infarction.9,20,21 Platelet activation with enhanced P-selectin and 
CD63 expression has been reported with TIA and stroke.10,22 In particular, large-artery 
atherosclerosis (TOAST1) and cardioembolism (TOAST2) are the most frequent causes of 
brain ischemia.20 In our patients, TOAST1 and TOAST2 showed significantly increased 
levels of GPVI compared to patients with non-ischemic events indicating a similar thrombotic 
and platelet activation state in patients with large artery atherosclerosis and cardioembolism 
as cause for ischemic stroke. However, GPVI expression seems to be inappropriate to assess 
the severity of stroke, since we found no correlation between platelet surface GPVI 
expression and the NIHSS.  
Early diagnosis of ischemic stroke with the help of adequate biomarkers may further 
improve early therapy and clinical outcome in patients. 
There are several therapeutic regimes discussed on the appropriate management of 
high-risk patients, for it is challenging to dissociate the reduction of the risk of arterial 
thrombosis and increase of the risk of hemorrhagic and bleeding complications.21,24,25 Adding 
another second antiplatelet (clopidogrel) or anticoagulant (warfarin) medication to aspirin 
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may significantly reduce the risk of upcoming adverse events.21 However, others found that 
the use of a dual antiplatelet therapy was rather effective in symptomatic patients to reduce 
the rate of myocardial infarction, stroke, or death from cardiovascular causes.24 It is tempting 
to speculate that the collective of patients with increased platelet activation may profit from a 
dual antiplatelet therapy.10 Similarly to the recent findings of our prospective study in patients 
with acute coronary syndrome (ACS), symptomatic patients of TIA or stroke with an initially 
enhanced GPVI platetet expression (MFI≥18.2) had a poorer clinical outcome that may be 
improved by an intensified and timely antithrombotic therapy.13 Our previous findings 
suggested that high pretreatment platelet activation is associated with elevated platelet 
aggregability indicating a low response to standard antiplatelet therapy, when the 
conventional antiplatelet regimen is not highly effective in high-risk patients of ACS.13,26  
Specific therapeutic medical strategy may significantly influence prognosis in 
reducing the risk of TIA or stroke. Thus, patients with a recent TIA or stroke benefited from 
the administration of 80 mg atorvastatin per day in the reduction of overall incidence strokes 
and cardiovascular events.27 The rather detrimental clinical outcome in our patients with 
increased GPVI expression was not caused by the medication since patients had been 
administered comparable therapeutic regimes consisting of statins and antiaggregatory 
therapy.  
Thus, future studies should unveil whether platelet-specific thrombotic GPVI might 
not only be a predictive biomarker but also a prognostic marker for further thromboischemic 
events. GPVI may help to define therapeutic strategies in patients with stroke. 
 
 
Conclusion 
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We found a significantly enhanced expression of the platelet collagen receptor GPVI in 
patients with TIA and stroke compared to patients with non-ischemic events. Expression 
levels of GPVI determined on admission are strongly associated with stroke, independent of 
conventional laboratory markers such as C-reactive protein, blood glucose, and creatine 
kinase. Patients with an elevated platelet GPVI expression level had a poorer clinical 
outcome. Determination of the platelet-specific thrombotic marker GPVI may be useful as a 
biomarker for cerebral ischemia. Future studies should substantiate GPVI for its potential role 
for risk prediction and consider a possible prognostic value in order to improve risk 
stratification and guidance of treatment in patients, e.g. in dual antiplatelet therapy. 
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Legends to the Figures 
 
Figure 1:  Figure 1:  Platelet Collagen Receptor Glycoprotein VI Expression is Elevated 
in Patients With TIA and Stroke 
(A) Platelets of patients with non-ischemic events (NI), transient ischemic attack 
(TIA) and stroke were stained for the collagen receptor (GPVI) and P-selectin (CD62P) using 
monoclonal antibodies conjugated either to FITC or PE. Two-color whole blood flow 
cytometry was performed according to a standardized protocol and results were expressed as 
mean fluorescence intensity (MFI). (B) Expression of GPVI in patients according to the Trial 
of Org10172 in Acute Stroke Treatment (TOAST) classification.2 Patients with large-artery 
atherosclerosis (TOAST1) and cardioembolism (TOAST2) have shown significantly 
increased GPVI levels in contrast to patients with non-ischemic events (NI). Whiskers present 
95% confidence intervals. (C) We found no correlation between platelet surface GPVI 
expression and the severity of stroke assessed by the National Institutes of Health Stroke Scale 
(NIHSS) (r=-0.19; p=0.789).15 
 
 
Figure 2: Receiver Operating Characteristic (ROC) Curve and Relative Risk 
(A) Levels of platelet surface expression of GPVI mean fluorescence intensity (MFI) 
represented in a receiver operating characteristic (ROC) curve. GPVI cut off value for stroke 
is found at 18.2 MFI. Area under curve is 0.683 (95%CI, 0.585 to 0.757). (B) Patients with 
increased GPVI levels (MFI≥18.2) had a 2.4-fold relative risk (95%CI, 1.4 to 4.2) for stroke, 
patients with lower GPVI (MFI<18.2) presented a value of 0.5 (95%CI, 0.4 to 0.7). 
 
Figure 3: Cumulative Event-Free Survival 
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Cumulative event-free survival considered stroke, myocardial infarction and cerebro-
/cardiovascular death in three-month follow-up by telephone interview (92.2%: 189 of 205 
patients). Patients with an elevated platelet GPVI expression level (MFI≥18.2) had a poorer 
clinical outcome than patients with a decreased GPVI expression (Log rank; p=0.045). 
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Table 1. Baseline Patients` Characteristics and Medical Treatment on Hospital Admission 
Characteristics 
       All  
    (n=205) 
 
        TIA 
      (n=18) 
 
       Stroke 
       (n=133) 
 
   Non-Ischemic 
        (n=54) 
 
Age – yrs 71.6±12.9*     68.2±16.2*      73.1±11.6*      68.8±15.1* 
Sex – no. (%) 
          
    Female 
  85 (41.5)          7 (38.9)        56 (42.1)        22 (40.7) 
    Male 120 (58.5)        11 (61.1)        77 (57.9)        32 (59.3) 
Cerebro-/Cardiovascular Risk  
Factors – no. (%)     
 Arterial Hypertension 144 (70.2)        13 (72.2)     103 (77.4)        28 (51.9) 
 Hyperlipidaemia 
  81 (39.5)          6 (33.3)       64 (48.1)        11 (20.4) 
 Diabetes 
  62 (30.2)          5 (27.8)       42 (31.6)        15 (27.8) 
 Family History of CVD 
  15 (7.3)          0       11 (8.3)          4 (7.4) 
    Smoking  
  42 (20.5)          2 (11.1) 
 
      31 (23.3) 
 
         9 (16.7) 
 
    Atrial Fibrillation   61 (29.8) 
 
         2 (11.1) 
 
      51 (38.3) 
 
         8 (14.8) 
 
    Coronary Artery Disease 
  68 (33.2)         2 (11.1)   52 (39.1)   14 (25.9) 
Medication – no. (%) 
    
ACE Inhibitors 
  49 (23.9)          2 (11.1)       32 (24.1)        15 (27.8) 
Angiotensin Receptor 
Blockers     9 (4.4)          1 (5.6)         5 (3.8)          3 (5.6) 
Beta Blockers 
  61 (29.8)          7 (38.9)       39 (29.3)        15 (27.8) 
Statins 
  34 (16.6)          6 (33.3)       20 (15)          8 (14.8) 
Aspirin 
  37 (18)          1 (5.6)       25 (18.8)        11 (20.4) 
Clopidogrel 
    3 (1.5)          0         2 (1.5)          1 (1.9) 
Vitamin K Antagonist 
  20 (9.8)          1 (5.6)       15 (11.3)          4 (7.4) 
 
*mean ± standard deviation. CVD denotes cerebro-/cardiovascular disease, ACE angiotensin converting enzyme 
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Table 2. Predictive Value of GPVI for the Development of Stroke 
Parameters  
 
     P Value 
 
Odds Ratio 
 
95% CI for Odds Ratio 
       Lower             Upper 
GPVI (MFI) 0.003 1.199 1.065 1.351 
C-reactive protein (mg/dL)  0.800 1.019 0.882 1.176 
Blood Glucose (mg/dL) 0.117 0.990 0.978 1.003 
Creatine Kinase (U/L) 0.333 0.999 0.997 1.001 
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Table 3. Results of Clinical Follow-up at 30 Days and 3 Months 
Endpoints 
      
     All 
    (n=189) 
 
GPVI 
MFI<18.2 
(n=93) 
GPVI 
MFI≥18.2 
(n=96) 
At 30 Days 
 
   
      Myocardial Infarction  
 
     3 (1.6%)   1 (1.1%)     2 (2.1%) 
      Stroke 
     4 (2.1%)      1 (1.1%)     3 (3.1%) 
      CV Death 
   7 (3.7%)   1 (1.1%) 6 (6.2%) 
      Composite MI/Stroke/CV Death 
   14 (7.4%)   3 (3.2%)   11 (11.5%) 
At 3 Months 
   
      Myocardial Infarction  
  5 (2.6%)   2 (2.2%)     3 (3.1%) 
      Stroke 
  6 (3.2%)      2 (2.2%) 4 (4.2%) 
      CV Death 11 (5.8%)   1 (1.1%)   10 (10.4%) 
      Composite MI/Stroke/CV Death 
  22 (11.6%)   5 (5.4%)   17 (17.7%) 
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Table 4. Medical Treatment of Follow-up Patients on Admission and after 3 Months               
 
Medication – no. (%) 
All 
(n=189) 
GPVI MFI<18.2 
(n=93) 
GPVI MFI≥18.2 
(n=96) 
  P Value 
 
On Admission 
                
ACE Inhibitors 
  47 (24.8)        21 (22.6)        26 (27.1)    0.055 
Angiotensin Receptor 
Blockers     8 (4.2)          3 (3.2)         5 (5.2)    0.177 
Beta Blockers 
  59 (31.2)        27 (29)       32 (33.3)    0.067 
Statins 
  32 (16.9)        18 (19.4)       14 (14.6)    0.833 
Aspirin 
  35 (18.5)          9 (9.7)       13 (13.5)    0.098 
Clopidogrel 
    3 (1.6)          2 (2.2)         1 (1)    0.270 
Vitamin K Antagonist 
  19 (10.1)          8 (8.6)       11 (11.5)    0.193 
At 3 Months 
   
          
 
  
ACE Inhibitors 
 
  69 (36.5) 
 
37 (39.8) 
 
32 (33.3) 
 
   0.074 
 
Angiotensin Receptor 
Blockers   15 (7.9)          8 (8.6)         7 (7.3)    0.508 
Beta Blockers 
  82 (43.4)        39 (41.9)       43 (44.8)    0.156 
Statins 
  54 (28.6)        25 (26.9)       29 (30.2)    0.122 
Aspirin 
  78 (41.3)        36 (38.7)       42 (43.8)    0.051 
Clopidogrel 
  14 (7.4)         6 (6.5)         8 (8.3)    0.219 
Vitamin K Antagonist 
  48 (25.4)        23 (24.7)       25 (26)    0.360 
Aspirin+Dipyridamole 
  25 (13.2)        11 (11.8)       14 (14.6)    0.146 
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